London, UK – 5 October 2022 – Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, today celebrated its expansion and growth with a Grand Opening at its new facilities in White City, West London.
Engitix purpose-designed mixed-use headquarters and R&D facilities of 13,000 sq ft at WestWorks at White City Place more than doubles the Company’s capacity. Engitix has operated from offices at WestWorks since 2020 and the move integrates its laboratories bringing its team of some 60 staff together at one site.
2022 has been a transformative year for Engitix. It closed a $54m Series A financing at the start of the year, with the proceeds being invested in the development of an internal drug discovery pipeline through IND-enabling studies, expansion of its ECM discovery platform and bioinformatics capabilities into new therapeutic areas, and growth of its team, facilities and operations, including the move to WestWorks. At the same time, it closed a strategic collaboration with Dompé farmaceutici S.P.A (“Dompé”) and, during the year it also announced a second collaboration and licensing agreement with Takeda to develop new anti-fibrotic therapies in inflammatory bowel disease.
Dr Giuseppe Mazza, co-founder and CEO of Engitix said, “The move to our own purpose-designed facilities in one of London’s most dynamic life science clusters underlines our achievements and reflects our growth and evolution from a platform to multi-asset, mutli-programmes, pre-clinical stage company, to become a global leader in the discovery and development of novel therapeutics for fibrosis and solid tumours.”
Stephen Brindle, COO at Engitix said: “Today’s Grand Opening celebrates a major milestone for our business. At Engitix, relationships are the foundation of accomplishment and critical to our mission to significantly improve the lives of fibrosis and solid tumour patients and their families. We have attracted an ambitious team with a wealth of technical and medical knowledge and a strong commercial mindset. Being located at White City Place gives us access to world class facilities, access to an established life sciences network, and will help us to grow and attract the best talent to Engitix.”
Engitix joins Autolus, Synthace, Vivan, InvoX Pharma, Novartis and Takeda (post acquisition of Gama Delta) at the WestWorks site which is next to Imperial College London’s new 23-acre campus, Hammersmith Hospital, and Scale Space, home to more life science companies such as DNAe and Avacta. The site is a partnership of Stanhope and Cadillac Fairview in developing life science hubs in the UK, not just at White City Place with recent investments in Cambridge Science Park and agreeing a joint venture with Thomas White Oxford Ltd to deliver Oxford North, a £700 million new global innovation district.
– ENDS –
Notes to Editors:
About Engitix Ltd
Engitix is developing a portfolio of internal and partnered drug discovery programmes in fibrosis and solid tumours using its pioneering human extracellular matrix (ECM) platform. The use of more physiologically relevant human in vitro models is transforming the ability to identify new targets, to develop more advanced treatments and to enable a more accurate prediction of the efficacy of therapeutic candidates. It has a strategic drug discovery partnership with Dompé farmaceutici where the internal drug development programmes of Engitix will be accelerated by leveraging Exscalate (Dompé’s AI-enabled high performance computing platform), and two discovery and development collaborations with Takeda in advanced fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH), and fibrostenotic Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis.
Established to commercialise cutting-edge research from the Institute for Liver and Digestive Health, Division of Medicine, University College London (UCL), Engitix is headquartered in Westworks, White City Place, London, UK. It has raised more than $60m in equity from investors including Netherton Investments (a fund investing on behalf of Mike Platt) and Dompé farmaceutici S.P.A.
For more information, please visit www.engitix.com
Follow us on LinkedIn
For more information:
At the Company
Giuseppe Mazza, CEO
Media enquiries (for Engitix)
Sue Charles, Charles Consultants
T: +44 7986 726585